←
David Mathai, MD1,380 posts
David Mathai, MD avatar

David Mathai, MD

@d_mathai

🌿 Medical Director, Psychiatry, Sattva Medicine 🔬 Psychedelic Therapy Researcher 📚 Baylor College of Medicine You and your experience matter.

◷ Joined January 2013▧ 35 Photos and videos
David Mathai, MD avatar
David Mathai, MD@d_mathai·18 Nov 2025

🚨 New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics

Post attachment
David Mathai, MD avatar
David Mathai, MD@d_mathai·15h

New in Psychopharmacology: does the experience matter for ketamine? In 3,637 adults with depression, more intense psychedelic experiences went with greater improvement. Observational, but a sign the experience deserves careful measurement. doi.org/10.1007/s00213-026-0…

Post attachment
David Mathai, MD avatar
David Mathai, MD@d_mathai·May 20

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3): sciencedirect.com/science/ar…

Dr. Rick Barnett, PsyD 😊 avatar
⟳ David Mathai, MD retweeted
Dr. Rick Barnett, PsyD 😊@drrickbarnett·Jan 7

Reported Safety Practices of Publicly Advertised Psychedelic Retreats jamanetwork.com/journals/jam… I find this study could be a useful springboard for deep discussions around safety and ethics, but NOT only from a western medical lens.

David Mathai, MD avatar
David Mathai, MD@d_mathai·Jan 3

🚨 New publication led by the OSU psychedelic center! "𝗨𝗦 𝗱𝗿𝘂𝗴 𝗽𝗼𝗹𝗶𝗰𝘆 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝗮𝗹𝗶𝗴𝗻 𝘄𝗶𝘁𝗵 𝗲𝘅𝗽𝗲𝗿𝘁𝘀’ 𝗿𝗮𝗻𝗸𝗶𝗻𝗴𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗵𝗮𝗿𝗺𝘀: 𝗔 𝗺𝘂𝗹𝘁𝗶-𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀" link.springer.com/article/10…

David Mathai, MD avatar
David Mathai, MD@d_mathai·18 Nov 2025

DISCLAIMER: This post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions related to mental health or treatment options.

BCM Ethics & Policy avatar
⟳ David Mathai, MD retweeted
BCM Ethics & Policy@BCMEthics·31 Mar 2025

🚨 New paper alert! 🚨 Check out the latest viewpoint by our Dr. McGuire, scholar Dr. Mathai, and collaborators on minimizing risk and harm in the use of psychedelics. Read more: onlinelibrary.wiley.com/doi/… #psychedelics #harmreduction

Shayla Love avatar
⟳ David Mathai, MD retweeted
Shayla Love@shayla__love·5 Mar 2025

Lots of people have been speculating about Elon Musk’s ketamine use, and so I wrote about what we do know about prolonged, heavy ketamine use in samples of recreational users. Many of these risks are well-known already in psychedelic circles. theatlantic.com/health/archi…

DoubleBlind avatar
⟳ David Mathai, MD retweeted
DoubleBlind@doubleblindmag·3 Mar 2025

Today in The Drop In: Beat-era poet and artist Gerd Stern’s final chapter, new research on why guilt during a trip might actually help you heal, and monkeys tapping into plant medicine. Plus, soul retrieval and what to know before working with Datura. newsletter.doubleblindmag.co…

Journal of Studies on Alcohol and Drugs avatar
⟳ David Mathai, MD retweeted
Journal of Studies on Alcohol and Drugs@JSADJournal·26 Feb 2025

“Bad trips” and guilt: Why difficult feelings during psychedelic use might actually be a good thing: Study @d_mathai @sdpnayak @n_sepeda @Drug_Researcher @JHPsychedelics @BCMEthics @unlimited_sci psypost.org/bad-trips-and-gu…